Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 4007-4016

  Jarzabek, Katarzyna ^a   Koda, Mariusz ^b   Walentowicz Sadlecka, Malgorzata ^c   Grabiec, Marek ^c   Laudanski, Piotr ^b   Wolczynski, Slawomir ^b  

^a INSTITUTE OF ANIMAL REPRODUCTION AND FOOD RESEARCH   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Aromatase; COX2; ERs (ER , ER ); Type 1 endometrial cancer

Indexed keywords

AROMATASE; CYCLOOXYGENASE 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA;

ADULT; AROMATASE GENE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATIONAL STUDY; COX2 GENE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ERALPHA GENE; ERBETA GENE; FEMALE; GENE OVEREXPRESSION; GENETIC MARKER; HORMONE PROTEIN COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MRNA EXPRESSION ASSAY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT;

EID: 84891481542     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0991-9     Document Type: Article

References (34)

1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-7.
2. Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335:640-9.
3. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer. 2001;84:975-81.
4. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996;88:1127-35.
5. Parazzini F, la Vecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol. 1991;41:1-16.
6. Park CK, Apte S, Acs G, Harris EER. Cancer endometrium. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna W, editors. Abeloff's clinical oncology. 4th ed. Philadelphia: Elsevier; 2008.
7. Weihua Z, Saji S, Mäkinen S, Cheng G, Jensen EV, Warner M, et al. Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci U S A. 2000;97:5936-41.
8. Matsumoto M, Yamaguchi Y, Seino Y, Hatakeyama A, Takei H, Niikura H, et al. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr Relat Cancer. 2008;15:451-63.
9. Bulun SE, Chen D, Lu M, Zhao H, Cheng Y, Demura M, et al. Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol. 2007;106:81-96.
10. Segawa T, Shozu M, Murakami K, Kasai T, Shinohara K, Nomura K, et al. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. Clin Cancer Res. 2005;11:2188-94.
11. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996;137:5739-42.
12. Singh A, Purohit A, Ghilchik MW, Reed MJ. The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer. 1999;6:139-47.
13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-9.
14. Llauradó M, Ruiz A, Majem B, Ertekin T, Colás E, Pedrola N, et al. Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol. 2012;358:244-55.
15. Jereczek-Fossa B, Badzio A, Jassem J. Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int J Gynecol Cancer. 1999;9:285-94.
16. Bulun SE, Imir G, Utsunomiya H, Thung S, Gurates B, Tamura M, et al. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol. 2005;95:57-62.
17. Jongen VH, Thijssen JH, Hollema H, Donker GH, Santema JG, van der Zee AG, et al. Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer? Int J Gynecol Cancer. 2005;15:529-36.
18. Pathirage N, di Nezza LA, Salmonsen LA, Jobling T, Simpson ER, Clyne CD. Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer. Fertil Steril. 2006;86:469-72.
19. Smuc T, Rizner TL. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol. 2009;301:74-82.
20. Watanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Sato S, et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol. 1995;146:491-500.
21. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78.
22. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19:3119-30.
23. Everett E, Tamimi H, Greer B, Swisher E, Paley P, Mandel L, et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2003;90:150-7.
24. Martra F, Kunos C, Gibbons H, Zola P, Galletto L, DeBernardo R, von Gruenigen V. (2008) Adjuvant treatment and survival in obese women with endometrial cancer: an international collaborative study. Am J Obstet Gynecol. 198:89. e1-8.
25. Münstedt K, Wagner M, Kullmer U, Hackethal A, Franke FE. Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes Control. 2008;19:909-16.
26. Crosbie EJ, Roberts C, Qian W, Swart AM, Kitchener HC, Renehan AG. Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer. 2012;48:853-64.
27. Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli VS, et al. Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol. 2011;121:586-94.
28. Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol. 2005;98:383-9.
29. Fowler JM, Ramirez N, Cohn DE, Kelbick N, Pavelka J, Ben-Shachar I, et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol. 2005;192:1262-73.
30. Knapp P, Chabowski A, Błachnio-Zabielska A, Walentowicz- Sadłecka M, Grabiec M, Knapp P. Expression of estrogen receptors (α, β), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus. Adv Med Sci. 2013;24:1-8.
31. Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene. 2001;20:6965-9.
32. Saegusa M, Okayasu I. Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium. Jpn J Cancer Res. 2000;91:510-8.
33. Kolkova Z, Noskova V, Ehinger A, Hansson S, Casslén B. G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua. Mol Hum Reprod. 2010;16:743-51.
34. Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, et al. Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome. Br J Cancer. 2012;106:1682-8.